1,068.90
+4.68%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Innova Captab
Its shares trade on NSE under the ticker INNOVACAP.NS. It has been listed since 29 December 2023. In the fiscal year to 31 March 2026, it reported revenue of ₹16.04bn and net income of ₹1.41bn. At that date it held total assets of ₹18.37bn and shareholders' equity of ₹10.91bn.
Innova Captab Ltd is a IN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Panchkula, Haryana. The company went IPO on 2023-12-29. Innova Captab Ltd is an integrated pharmaceutical company. The firm is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The company has presence across the pharmaceuticals value chain, including research and development, manufacturing, drug distribution and marketing and exports. Its business includes CDMO business, domestic branded generics business, and international branded generic product business. Its CDMO business provides research, product development and manufacturing services. Its branded generics business consists of the development, manufacture and distribution of generic formulation products, which are marketed and distributed in India under its own brand names through online and offline channels. Its generic drug products are also available online through various e-commerce pharmacy sites. The company has developed a diversified branded generics product portfolio including Tablets, capsules, dry syrups, dry powder injection, ointments and liquid orals.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 29 Dec 2023
- Website
- innovacaptab.com ↗
Leadership
Pay as last reported
- Mr. Lokesh BhasinChief Financial Officer
- Ms. Neeharika ShuklaCompliance Officer, Company Secretary
- Mr. Vinay LohariwalaManaging Director
- Mr. Manoj LohariwalaWhole-Time Director, since 2009
- Mr. Jayant RaoWhole-Time Director, since 2020
- Anup AgarwalDirector
- Mr. Archit AggarwalDirector
- Mr. Gian AggarwalDirector, since 2023
- Mr. Sudhir BassiDirector
- Mr. Shirish BelapureDirector
- Priyanka DixitDirector
- Mahendar KorthiwadaDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Innova Captab Ltd's diversified branded generics portfolio includes tablets, capsules, and dry syrups for domestic markets.
- The company's CDMO business offers research, development, and manufacturing services for pharmaceutical products.
- Innova Captab Ltd has a strong presence across the pharmaceuticals value chain from R&D to exports.
Weaknesses
- The company's domestic branded generics business relies on online and offline channels for marketing and distribution.
- Innova Captab Ltd's international branded generic product business faces competition in global markets.
- The company's e-commerce pharmacy presence is limited to online platforms for generic drug products.
Opportunities
- Innova Captab Ltd can expand its CDMO services to new international markets for pharmaceutical manufacturing.
- The company can leverage its diversified product portfolio to enter new geographic segments in India.
- Growing demand for generic drugs in India presents an opportunity for Innova Captab Ltd's branded generics business.
Threats
- Competition from established pharmaceutical companies in the domestic branded generics market.
- Regulatory changes in the Indian pharmaceutical industry could impact Innova Captab Ltd's operations.
- Global economic downturns may affect the international branded generic product business.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.